1naresh
Array ( [urn:ac.highwire.org:guest:identity] => Array ( [runtime-id] => urn:ac.highwire.org:guest:identity [type] => guest [service-id] => ajnr-ac.highwire.org [access-type] => Controlled [privilege] => Array ( [urn:ac.highwire.org:guest:privilege] => Array ( [runtime-id] => urn:ac.highwire.org:guest:privilege [type] => privilege-set [privilege-set] => GUEST ) ) [credentials] => Array ( [method] => guest ) ) ) 1nareshArray ( [urn:ac.highwire.org:guest:identity] => Array ( [runtime-id] => urn:ac.highwire.org:guest:identity [type] => guest [service-id] => ajnr-ac.highwire.org [access-type] => Controlled [privilege] => Array ( [urn:ac.highwire.org:guest:privilege] => Array ( [runtime-id] => urn:ac.highwire.org:guest:privilege [type] => privilege-set [privilege-set] => GUEST ) ) [credentials] => Array ( [method] => guest ) ) )Table 5:Outcomes
PGLA Coated Hydrogel Coated PGA Coated Fibered Num/Denom (%) Num/Denom (%) Num/Denom (%) Num/Denom (%) Clinical outcome reported 8/14 studies 2/10 studies 0/2 studies 1/1 Good outcome rate 307/495 (62) 58/63 (92) NS 353/463 (76) Rebleeds 7 in 8 studies 3 in 9 studies 0 in 2 studies NS Rebleed rate (% pa) 7 in 432 years of follow-up (1.6) 3 in 256 years of follow-up (1.2) 0 in 51 years of follow-up (0) NS Aneurysm retreatment 63 in 8 studies 13 in 7 studies 1 in 1 study DNE By total aneurysms 63/634 (10) 13/400 (3) 1/55 (2) By aneurysms followed up 63/472 (13) 13/268 (5) 1/55 (2)
Note:—pa indicates per annum.